June 3, 2021 08:00 AM EDTUpdated 08:23 AM

Bayer doubles down on radiotherapy with acquisitions of 2 tiny biotech players built around research from Cornell

Kyle Blankenship

With #ASCO21 just days away, Swiss drugmaker Novartis is set to unveil late-stage data for its highly touted radioligand, potentially charting a new course for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bayer doubles down on radiotherapy with acquisitions of 2 tiny biotech players built around research from Cornell

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Bay­er dou­bles down on ra­dio­ther­a­py with ac­qui­si­tions of 2 tiny biotech play­ers built around re­search from Cor­nell

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bayer doubles down on radiotherapy with acquisitions of 2 tiny biotech players built around research from Cornell